Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Net Margin (2016 - 2025)

Guided Therapeutics' Net Margin history spans 16 years, with the latest figure at 202.71% for Q4 2025.

  • On a quarterly basis, Net Margin rose 6979729.0% to 202.71% in Q4 2025 year-over-year; TTM through Dec 2025 was 430.25%, a 3658404.0% increase, with the full-year FY2025 number at 430.25%, up 3658404.0% from a year prior.
  • Net Margin hit 202.71% in Q4 2025 for Guided Therapeutics, up from 1308.33% in the prior quarter.
  • Over the last five years, Net Margin for GTHP hit a ceiling of 202.71% in Q4 2025 and a floor of 70000.0% in Q4 2024.
  • Historically, Net Margin has averaged 16039.17% across 5 years, with a median of 4025.0% in 2023.
  • Biggest five-year swings in Net Margin: tumbled -6853438bps in 2024 and later surged 6979729bps in 2025.
  • Tracing GTHP's Net Margin over 5 years: stood at 848.33% in 2021, then plummeted by -4041bps to 35133.33% in 2022, then soared by 96bps to 1465.62% in 2023, then plummeted by -4676bps to 70000.0% in 2024, then soared by 100bps to 202.71% in 2025.
  • Business Quant data shows Net Margin for GTHP at 202.71% in Q4 2025, 1308.33% in Q3 2025, and 731.62% in Q2 2025.